Sarepta Therapeutics (NASDAQ:SRPT) is set to announce its earnings results after the market closes on Monday, March 1st. Analysts expect the company to announce earnings of ($1.99) per share for the quarter.
Shares of Sarepta Therapeutics stock traded down $4.58 during trading hours on Tuesday, hitting $78.53. The company's stock had a trading volume of 7,722 shares, compared to its average volume of 2,918,746. Sarepta Therapeutics has a twelve month low of $78.06 and a twelve month high of $181.83. The firm has a fifty day moving average of $97.14 and a 200-day moving average of $134.68. The stock has a market cap of $6.20 billion, a price-to-earnings ratio of -10.37 and a beta of 2.01. The company has a debt-to-equity ratio of 0.79, a quick ratio of 5.56 and a current ratio of 6.14.
In other news, insider Joseph Bratica sold 1,125 shares of the business's stock in a transaction on Tuesday, December 8th. The stock was sold at an average price of $160.00, for a total transaction of $180,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.90% of the company's stock.
Several research analysts have commented on the stock. Cantor Fitzgerald lowered their price target on shares of Sarepta Therapeutics from $217.00 to $128.00 and set an "overweight" rating for the company in a report on Friday, January 8th. Piper Sandler upped their price objective on shares of Sarepta Therapeutics from $200.00 to $240.00 and gave the stock an "overweight" rating in a research report on Monday, January 4th. Cowen lowered their price target on shares of Sarepta Therapeutics from $213.00 to $114.00 and set an "outperform" rating on the stock in a research note on Friday, January 8th. SVB Leerink cut their price objective on Sarepta Therapeutics from $197.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, January 8th. Finally, Berenberg Bank assumed coverage on Sarepta Therapeutics in a report on Wednesday, November 11th. They issued a "hold" rating and a $140.00 price target for the company. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of "Buy" and an average price target of $160.38.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Featured Article: Special Purpose Acquisition Company (SPAC)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Best Growth Stocks - Best Stocks to Buy Now
The stock market has been growing since the New York Stock Exchange opened its doors in 1817. Sometimes, a stock will outpace the rest of the market in terms of growth. These skyrocketing securities—or the ones that analysts expect to skyrocket—are called growth stocks.
What Every Investor Needs to Know About Growth Stocks
Growth stocks are a great opportunity for an investor to make money in the stock market, but you’ve got to know what you’re going to buy or sell. A good understanding of growth stocks will help you get there.
At the beginning of a bull market, you can almost choose stocks randomly and find yourself a winner. Now that we are entering the current bull market's ninth year, growth stocks have appreciated considerably. It's becoming far more challenging to find stocks with real opportunities for appreciation.
Growth companies are still largely outperforming their value counterparts in the United States and the rest of the world largely because of low-interest rates, improved corporate earnings, and global economic growth. Over the last five years, the S&P 500 Growth Index has returned 14.22% per year. During the same time, the S&P 500 Value Index returned just 12.94%.
Now that the bull market is now nearly a decade old, stocks have become very expensive. Value investors are largely sitting on the sidelines, and growth investors have a hard time figuring out where the remaining growth opportunities exist.
If you are looking for growth stocks in an increasingly small field, we have identified the 10 best growth stocks to buy right now based on their expected earnings growth over the next several years. These companies are all growing rapidly and will likely see double-digit earnings growth next year.
View the "Best Growth Stocks - Best Stocks to Buy Now".